VALLEY FORGE, Pa.--(BUSINESS WIRE)--Aug. 7, 2008--The Board of
Directors of AmerisourceBergen Corporation (NYSE:ABC) today declared a
cash dividend of $0.075 per share on Common Stock, payable September
2, 2008 to shareholders of record at the close of business on August
18, 2008.
About AmerisourceBergen
AmerisourceBergen is one of the world's largest pharmaceutical
services companies serving the United States, Canada and selected
global markets. Servicing both pharmaceutical manufacturers and
healthcare providers in the pharmaceutical supply channel, the Company
provides drug distribution and related services designed to reduce
costs and improve patient outcomes. AmerisourceBergen's service
solutions range from pharmacy automation and pharmaceutical packaging
to reimbursement and pharmaceutical consulting services. With more
than $70 billion in annualized revenue, AmerisourceBergen is
headquartered in Valley Forge, PA, and employs approximately 11,200
people. AmerisourceBergen is ranked #28 on the Fortune 500 list. For
more information, go to www.amerisourcebergen.com.
Forward-Looking Statements
This news release may contain certain "forward-looking statements"
within the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. These statements
are based on management's current expectations and are subject to
uncertainty and changes in circumstances. Actual results may vary
materially from the expectations contained in the forward-looking
statements. The following factors, among others, could cause actual
results to differ materially from those described in any
forward-looking statements: changes in pharmaceutical market growth
rates; competitive pressures; the loss of one or more key customer or
supplier relationships; changes in customer mix; customer or supplier
defaults or insolvencies; changes in pharmaceutical manufacturers'
pricing and distribution policies or practices; adverse resolution of
any contract or other disputes with customers (including departments
and agencies of the U.S. Government) or suppliers; regulatory changes
(including increased government regulation of the pharmaceutical
supply channel); government enforcement initiatives (including (i) the
imposition of increased obligations upon pharmaceutical distributors
to detect and prevent suspicious orders of controlled substances (ii)
the commencement of further administrative actions by the U. S. Drug
Enforcement Administration seeking to suspend or revoke the license of
any of the Company's distribution facilities to distribute controlled
substances, (iii) the commencement of any enforcement actions by any
U.S. Attorney alleging violation of laws and regulations regarding
diversion of controlled substances and suspicious order monitoring),
or (iv) the commencement of any administrative actions by the board of
pharmacy of any state seeking to suspend, revoke or otherwise restrict
the ability of any of the Company's distribution facilities or
businesses to distribute or dispense pharmaceuticals in such state;
changes in U.S. government policies (including reimbursement changes
arising from federal legislation, including the Medicare Modernization
Act and the Deficit Reduction Act of 2005); changes in regulatory or
clinical medical guidelines, reimbursement practices and/or labeling
for the pharmaceuticals we distribute, including
erythropoiesis-stimulating agents (ESAs) used to treat anemia
patients; price inflation in branded pharmaceuticals and price
deflation in generics; fluctuations in market interest rates;
operational or control issues arising from the Company's outsourcing
of information technology activities; success of integration,
restructuring or systems initiatives; fluctuations in the U.S. dollar
- Canadian dollar exchange rate and other foreign exchange rates;
economic, business, competitive and/or regulatory developments in
Canada, the United Kingdom and elsewhere outside of the United States;
acquisition of businesses that do not perform as we expect or that are
difficult for us to integrate or control; the inability of the Company
to complete the divestiture of its PMSI workers' compensation
business; an increase in the impairment charge related to PMSI if the
divestiture is not completed; any disruption to or other adverse
effects on the Company related to its exit from the PMSI workers'
compensation business and classification of that business as a
discontinued operation; the incurrence of additional costs, expenses
or liabilities in the future related to discontinued operations; the
inability of the Company to successfully complete any other
transaction that the Company may wish to pursue from time to time;
changes in tax legislation or adverse resolution of challenges to our
tax positions; and other economic, business, competitive, legal, tax,
regulatory and/or operational factors affecting the business of the
Company generally. Certain additional factors that management believes
could cause actual outcomes and results to differ materially from
those described in forward-looking statements are set forth (i) in
Item 1A (Risk Factors) in the Company's Annual Report on Form 10-K for
the fiscal year ended September 30, 2007 and elsewhere in that report
and (ii) in other reports filed by the Company pursuant to the
Securities Exchange Act of 1934.
CONTACT: AmerisourceBergen Corporation
Michael N. Kilpatric, 610-727-7118
mkilpatric@amerisourcebergen.com
SOURCE: AmerisourceBergen Corporation